What Pegasus Laboratories does

Pegasus Laboratories, Inc. is a Pensacola, Florida-based veterinary pharmaceutical manufacturer and full-service Contract Development and Manufacturing Organization (CDMO) founded in 1986 and operating as a wholly owned subsidiary of PBI-Gordon Companies, Inc. The company employs more than 100 people and is 100% employee-owned via an ESOP. It sells proprietary veterinary pharmaceuticals through two brands — PRN® Pharmacal (specialty products in behavior, urinary incontinence, seizure management, and animal wellness) and Sē·Qual™ (generic drug line) — and provides branded CDMO services to third-party animal-health innovators seeking development, scale-up, clinical and commercial manufacturing, and regulatory support from concept through commercialization.

Pegasus operates a single DEA-approved CGMP facility at 8809 Ely Road, Pensacola, Florida, with multi-dosage-form capability spanning solid oral (tablets, boluses, granulation, direct compression; lot sizes up to 2,000 kg), topical and semi-solid forms (up to 4,000 kg), and liquid oral forms (solutions, suspensions, emulsions), plus custom packaging (tubes, bottles, pen applicators, metered-dose systems, vials, syringes). Regulatory certifications cover FDA, EMA, Health Canada, Japan, and Australia. The company holds two notable regulatory firsts: KBroVet® (potassium bromide chewable tablets) is the first FDA fully approved pharmaceutical for canine idiopathic epilepsy (full approval February 2026, labeling transition April–May 2026), and Liavium®-CA1 (pregabalin chewable tablets) is the first FDA conditionally approved pregabalin for veterinary use (May 2026), acquired via the 2025 TriviumVet acquisition.

The business model is a hybrid of branded product sales and contract services. Revenue is generated through (1) sale of branded veterinary pharmaceuticals via a direct commercial sales force (including a dedicated VP of Sales and Commercial Operations) distributing through veterinary practice channels domestically, with international reach supported through multi-jurisdictional certifications, and (2) project-based CDMO engagements sold via direct B2B engagement to animal-health innovators, pharmaceutical companies, and biotech firms. Specific pricing is quote-based and not publicly disclosed. The company is privately held under PBI-Gordon Companies, has no external funding rounds on record, and is governed by an ESOP with two-year partial / six-year full vesting.

Name

Pegasus Laboratories

Legal name

Pegasus Laboratories, Inc.

Website

https://pegasuslabs.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

101–250 employees

Short description

Pegasus Laboratories is a Pensacola, Florida-based veterinary pharmaceutical manufacturer and CDMO serving veterinary practices and animal health innovators. Operating a DEA-approved CGMP facility, it produces FDA-approved branded products like KBroVet® and Liavium®-CA1 as a subsidiary of PBI-Gordon Companies.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Contract manufacturing services
• Pharmaceutical CDMO
• Veterinary drug development

Headquarters

HQ city

Pensacola

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Branded Veterinary Pharmaceuticals (PRN® Pharmacal & Sē·Qual™): Revenue from selling proprietary and generic veterinary pharmaceutical products and supplements. PRN® Pharmacal focuses on specialized products and drug therapies addressing overlooked veterinary medical needs in areas including behavior, urinary incontinence, seizure management, and animal wellness. Sē·Qual™ provides the generic drug line domestically manufactured by a proven animal health industry leader.
2. CDMO Contract Manufacturing Services: Revenue from providing full-service contract development and manufacturing services to third-party animal health organizations. Services include research and development, scale-up and technology transfer, clinical and commercial manufacturing, validation services, quality control, quality assurance, and regulatory support (FDA, EMA, Health Canada, Japan, Australia). Partners include innovators in the animal health space seeking turn-key product development and manufacturing.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Pegasus Laboratories develops, manufactures, and sells proprietary veterinary pharmaceutical products through its PRN Pharmacal and Sē·Qual brands, addressing areas such as behavior, urinary incontinence, seizure management, and animal wellness. The company also operates as a full-service Contract Development and Manufacturing Organization (CDMO), providing end-to-end product development and manufacturing services for animal health partners in a DEA-approved CGMP facility.

Product overview

Pegasus Laboratories is a veterinary pharmaceutical company operating through two primary product brands: PRN Pharmacal (specialty pharmaceuticals and supplements for behavior, urinary incontinence, seizure management, and other animal wellness areas) and Sē Qual (generic drug line). Key pharmaceutical products include KBroVet (potassium bromide) for canine idiopathic epilepsy and Liavium-CA1 (pregabalin) for canine neurological pain conditions. The company also operates a Contract Development and Manufacturing Organization (CDMO) division offering full-service product development and manufacturing for partners in the animal health industry.

Differentiator

Problem solved

Functional benefit

Brands

• PRN Pharmacal: A leader in animal health, pharmaceuticals, and supplements, focused on specialized products and drug therapies that address overlooked veterinary medical needs.
• Sē·Qual

Products and services

• PRN Pharmacal

Quantifiable outcome

• KBroVet® addresses approximately 2.1 million dogs affected by idiopathic epilepsy in the United States
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• TriviumVetcoreStrategic or Co-development Partner · 1 January 2025Pegasus Laboratories acquired TriviumVet in 2025, expanding its portfolio of innovative treatments in pet health. Through this acquisition, Pegasus gained Liavium®-CA1 (pregabalin chewable tablets), which received FDA conditional approval as the first pregabalin for veterinary use. Pegasus is conducting a pivotal clinical trial across investigator sites in the United States for full approval, while legally marketing the product under conditional approval.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Ceva Santé Animale: Global top-five animal health company with its own veterinary pharmaceutical manufacturing and a CDMO-style services offering — Pegasus competes in both branded vet pharma (behavior/seizure) and as a contract manufacturer for third parties.
• Virbac: Established global animal health company with broad companion-animal pharmaceutical portfolio and dedicated manufacturing sites, overlapping with Pegasus in specialty vet pharma and CGMP contract manufacturing.
• Phibro Animal Health: Public, diversified animal health company combining branded pharma, vaccines, and nutritional specialties with in-house manufacturing — overlaps with Pegasus's mix of branded pharmaceuticals and CGMP manufacturing.

Direct peers

• Dechra Pharmaceuticals: Specialty veterinary pharmaceutical company with strong franchises in canine endocrinology, dermatology, and CNS — directly comparable to Pegasus's focus on canine specialty therapeutics and behavior/urinary/seizure categories.
• Vetoquinol: Mid-cap specialty veterinary pharmaceutical manufacturer marketing branded products to companion animal practices globally, with in-house manufacturing and CDMO-adjacent capabilities — closely aligned with Pegasus's PRN Pharmacal and Sē·Qual branded model.
• Norbrook Laboratories: Privately held veterinary pharmaceutical manufacturer with multi-dosage-form CGMP production and CDMO services — directly comparable to Pegasus's contract manufacturing platform and branded vet pharma distribution.
• Bimeda Animal Health: Global veterinary pharmaceutical manufacturer offering branded generics and specialty pharmaceuticals across companion and production animals — comparable manufacturer-distributor profile to Pegasus with multi-jurisdictional regulatory licenses.
• Chanelle Pharma: Privately owned veterinary pharmaceutical manufacturer and CDMO offering generic and branded products across multiple dosage forms — closely comparable to Pegasus's combination of branded vet pharma and contract manufacturing.

Regional players

• Huvepharma: Animal health pharmaceutical manufacturer with growing veterinary specialty portfolio and European manufacturing footprint — comparable in pharma manufacturing scale and companion-animal focus to Pegasus.

Emerging players

• Companion Animal Health (TriviumVet-alike specialty vet biotechs): Specialty veterinary biotech focused on canine CNS disorders (e.g., Chiari-like malformation/syringomyelia) — directly comparable in therapeutic focus and pipeline stage to the TriviumVet assets now under Pegasus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pegasus Laboratories